Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal groups A and C and haemophilus b conjugate vaccine (Zhifei Lvzhu)
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal groups A and C and haemophilus b conjugate vaccine (MenAC-Hib) is a trivalent combination conjugate vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical. It is designed for the active immunization of infants and young children against invasive diseases caused by *Neisseria meningitidis* serogroups A and C and *Haemophilus influenzae* type b (Hib). The vaccine consists of purified capsular polysaccharides from these three pathogens, each individually conjugated to a tetanus toxoid carrier protein. This conjugation converts the polysaccharides from T-cell independent to T-cell dependent antigens, significantly enhancing immunogenicity and inducing immunological memory in infants as young as two months of age. It was the first AC-Hib triple vaccine approved globally and is a key component of pediatric vaccination programs in China.
- Brand names
- Xifeibei
- Other names
- MenAC-Hib vaccineAC-Hib vaccineMeningococcal Groups A and C and Haemophilus b Conjugate VaccineMeningococcal Groups A and C and Haemophilus influenzae type b Conjugate Vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)pMHCII (Carrier protein peptide-Major Histocompatibility Complex class II complex)
Beyond the preview
Go deeper on meningococcal groups A and C and haemophilus b conjugate vaccine (Zhifei Lvzhu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal groups A and C and haemophilus b conjugate vaccine (Zhifei Lvzhu).